Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera April 28, 2026
IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer April 21, 2026
Crossbow Therapeutics raised $77 million in Series B financing to support completion of CROSSCHECK‑001 Ph 1 clinical trial of CBX‑250, and accelerate development of additional T‑Bolt™ immunotherapies March 24, 2026
Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported March 17, 2026
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio March 10, 2026
FDA completes 30-day safety review of two IND applications for CXCR4-targeted theranostic program in hemato-oncology; proposed clinical study may proceed March 3, 2026
AstraZeneca announced $15B investment in China through 2030 to expand medicines manufacturing and R&D February 1, 2026
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Gen Bi-and Multi-Functional Fusion Protein Pipeline February 1, 2026
Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers January 25, 2026
Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies January 18, 2026
First US Commercial Sale of KOMZIFTI™ Triggers $135M Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin December 9, 2025
Leukogene Therapeutics Receives Strategic Funding from SCRA to Accelerate Development of Cancer Immunotherapy Pipeline November 18, 2025
Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies November 9, 2025
Enrollment in cohorts 1 & 2 of GTB-3650 Ph 1 Trial in Patients with R/R CD33 Expressing Heme Malignancies Completed October 15, 2025
FDA Accepts BLA for Priority Review for Orca-T® to Treat Heme Malignancies; PDUFA date April 6, 2026 October 8, 2025
First patient dosed in trial of huCART19-IL18 cells in the treatment of heme cancers September 10, 2025
